OncRef

Clinical Trial: NCT03639948

Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer

Status:

UNKNOWN

Phase:

Phase 2

Lead Sponsor:University of Kansas Medical Center
Information Provided By:University of Kansas Medical Center
Last Update Posted:2024-04-11

Study Overview

Brief Summary

The standard treatment for women with stage I, II, and III triple-negative breast cancer (TNBC) includes chemotherapy and surgery, with or without radiation therapy. However, because TNBC is usually more aggressive, harder to treat, and more likely to come back, it is associated with poor long-term outcomes (survival rates) when compared to other types of breast cancer. Therefore, researchers are studying how new drugs and treatment combinations can improve the outcome of patients with TNBC. This study will test effectiveness of immune therapy (Pembrolizumab is an "immunotherapy" that is expected to work with the body's immune system to help fight cancer) in combination with chemotherapy given before surgery.

Official Title

Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer

Conditions

Triple-negative Breast Cancer

Intervention / Treatment

  • Drug: Carboplatin
  • Drug: Docetaxel
  • Drug: Pembrolizumab
  • Drug: Pegfilgrastim

Other Study ID Numbers

  • IIT-2017-NeoPACT

Start Date (Actual)

2018-09-04

Primary Completion Date (Actual)

2022-01-27

Study Completion Date (Estimated)

2024-11

Enrollment (Actual)

120

Study Type

Interventional

Phase

Phase 2